VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 14, 2013) -
NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA
Premier Diagnostic Health Services Inc. ("PDH") (CNSX:PDH) today announces that, subject to regulatory approval, it will grant a total of 3,250,000 options to purchase common shares of the Company at an exercise price of $0.05 per share to directors, officers, consultants and employees pursuant to the Company's stock option plan (the "Optionees"). The Options will have a term of five years from April 15, 2013 (the "Term") and will vest over a period of 60 months as follows: 20% on the date of issue and 20% every year thereafter in the Term.
The Optionees Denis Tusar, Geoffrey P. Waters, Ross A. Greenwood, Ian D. Robertson, and Maya Butterfield are directors of the Company and have each disclosed in writing via Declarations of Interest the nature and extent of their interest in the Stock Options Grant.
About Premier Diagnostic Health Services Inc. ("PDH")
PHD is a Canadian company that provides advanced medical diagnostic tools utilizing of PET/CT Technology and/or MRI Technology and related diagnostic skills in Canada and, in partnership with hospitals and clinics in the Peoples Republic of China. The company's vision is to provide services and that support "improving medical decisions" around the world. The company's approach involves building long-term relationships covering management, quality, and financial services that are necessary to build, operate, and grow hospitals' and Clinics' diagnostic capacity and capability.
Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Premier.